Aeterna Zentaris Inc. (AEZS) Fundamentals

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
SHARE INFORMATION
Market Cap$ 23,296,086
Shares Outstanding121,397,007
Float121,278,087
Percent Float99.9%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 5,118,702
Latest Fiscal EPS$ 0.00
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions42
Institutional Holdings Date2022-05-31
Institutional Bought Previous 3 Months75,406
Institutional Holdings Percent1.1%
Institutional Sold Previous 3 Months782,404
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned3,595,318
TRADING INFO
52 Week High$ 0.98
52 Week Low$ 0.16
52 Week High Change$ -78.91
21 Day Moving Average$ 0.1905
21 Day Extended Moving Average$ 0.194359
50 Day Moving Average$ 0.2398
50 Day Extended Moving Average$ 0.233674
200 Day Moving Average$ 0.407333
200 Day Extended Moving Average$ 0.402457
10 Day Average Volume529,460
20 Day Average Volume520,496
30 Day Average Volume765,388
50 Day Average Volume659,172
Alpha-0.009958
Beta1.6503
Standard Deviation0.281046
R20.077324
7 Day Price Change$ 0.017
7 Day Percent Change9.72%
21 Day Price Change$ -0.0022
21 Day Percent Change-1.13%
30 Day Price Change$ -0.0214
30 Day Percent Change-10.03%
Month to Date Price Change$ -0.0146
Month to Date Percent Change-7.07%
Quarter to Date Price Change$ -0.1757
Quarter to Date Percent Change-47.8%
180 Day Price Change$ -0.2283
180 Day Percent Change-54.33%
200 Day Price Change$ -0.2081
200 Day Percent Change-52.03%
Year to Date Price Change$ -0.1634
Year to Date Percent Change-45.99%

Aeterna Zentaris Inc. (AEZS) Key Ratios

PROFITABILITY
EBIT Margin-194.6%
EBITDA Margin-191.7%
Pre-Tax Profit Margin-710.5%
Profit Margin Count0.0%
Gross Margin97.3%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 5,993,185
Revenue Per Share$ 0.0494
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.50
Total Debt To Equity0.00
Int Coverage-887.80
Current Ratio11.80
Leverage Ratio1.40
Quick Ratio11.60
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-2.70
Enterprise Value$ -39,103,642
Price to Sales3.8871
Price to Free Cash-2.50
PE High Last 5 Years21.90
Price To Book0.40
Price To Cash Flow9.90
PE Low Last 5 Years-2.90
Price to Tangible Book0.50
MANAGEMENT EFFECTIVENESS
Receivables Turnover2.90
Invoice Turnover0.80
Assets Turnover0.10
Return Assets-12.05
Return on Equity-16.79
Return on Capital-16.24

Aeterna Zentaris Inc. (AEZS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOKlaus Paulini
Emplyoees17
Last AuditUQ
CIK0001113423
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Addressc/o Norton Rose Fulbright Canada, LLP
222 Bay Street
Toronto, ON M5K 1E7
Websitehttps://www.zentaris.com
Facsimile-
Telephone+1 843 900-3223
EmailIR@aezsinc.com


Your Recent History
NASDAQ
AEZS
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.